logo
Share SHARE
FONT-SIZE Plus   Neg

GE Healthcare Reveals Phase 3 Results For Imaging Agent Flutemetamol

GE Healthcare, a unit of diversified conglomerate General Electric Co. (GE), Wednesday released results from four pooled brain biopsy studies and results from a brain autopsy study of the investigational PET amyloid imaging agent, flutemetamol.

The results revealed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

The data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease in living patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply higher at the open, stocks continue to see notable strength in mid-day trading on Wednesday. Buying interest has waned from earlier in the session, however, leading the major averages to pull back well off their highs. Former Florida Gov. Jeb Bush and businessman Donald Trump top the list of Republican presidential candidates in a new CNN/ORC International poll, although both are well behind Hillary Clinton in potential general election matchups. Confusion refuses to die down in Europe even after crucial deadlines were missed and hapless Greeks stare into an uncertain future for their country, while other Europeans try to preserve the sanctity of the union and the euro.
comments powered by Disqus
RELATED NEWS
Trade GE now with 
Follow RTT